Detailed background:
Question: What is the difference between lymphoma and non-Hodgkins lymphoma?
We have someone in our family who has been diagnosed in the past with non-Hodgkins lymphoma and would like to know the difference. Are the
treatments and prognosis the same?
Answer: Lymphoma is the broadest category of a family of related blood
cancers. That is it is any blood cancer that involves lymphocytes (the cell
type of origin) that is found primarily in the lymphatic system. It includes all
the subtypes or variations of lymphoma, about 40 different kinds.
The difference is in the type of lymphocytes involved - the so called
cell of origin.
In Hodgkin's disease, the abnormal lymphocyte is the Reed-Sternberg
cell (a B lymphocyte). This particular lymphocyte isn't found in
other types of lymphomas. All other types of lymphomas are
called non-Hodgkin's (NHL). There are about 30 subtypes of NHL.
Identifying the correct type of lymphoma is important because
treatment for Hodgkin's and non-Hodgkin's can be very different.
Pathologists can distinguish between Hodgkin's and non-Hodgkin's by
examining the cell sample from a biopsy under a microscope.
Lymphomas
Hodgkins (often curable)
Nodular Sclerosis,
Mixed Cellularity, Lymphocyte Depleted, Lymphocyte Predominant
Non-Hodgkins
Diffuse large b-cell (aggressive)
Follicular (indolent)
Mantle Cell
(aggressive or indolent)
MALT (indolent)
T-cell and NK-cell types
. . .
Other ways to categorize lymphomas are by the rate of growth: indolent, intermediate, and
aggressive.
Another ways is by areas of presentation: such as CNS (central nervous system), which is rare,
and MALT which presents in mucosal linings, such as the stomach.
Anther way to classify is by lymphocyte type: b-cell, t-cell, NK-cell.
(B-cell is most common).
Treatments for the various subtypes of lymphoma can vary significantly.
This group supports all types of lymphoma. Or does it's best to find
and post evidence-based information as questions comes in.
CATEGORIES OF LYMPHOMA
- Based primarily on WHO
|
Incidence
per year
|
Mortality
per year
|
Percentage of NHL
|
Hodgkin's
lymphomas - Reed-Sternberg cell
|
7,000 |
1,300 |
- |
Non-Hodgkin's
Lymphomas (NHL) B-cell
and T-cell types
|
54,000 |
24,000 |
100% |
B-cell NHL
|
45,900 |
|
85% |
T-cell NHL
|
6,885 |
|
15% |
Aggressive (fast-growing)
- High or intermediate grade B-cell or T- cell NHL
|
32,400 |
|
60% |
Indolent (slow-growing)
- Low grade B-cell or T-cell NHL
|
21,600 |
|
40% |
|
Most common NHL types:
|
Most Common
Grade
|
Incidence
per year
|
Mortality
per year
|
Percentage of NHL
|
| Diffuse
large B-cell |
High |
|
|
31% |
| Follicular
cell B-cell (Center cell) |
Low |
|
|
22% |
|
Precursor B-cell and T-cell NHL:
|
Most Common
Grade
|
Incidence
per year
|
Mortality
per year
|
Percentage of NHL
|
| Lymphoblastic
lymphoma - B-cell - can lead to CNS type * |
High |
|
|
|
| Lymphoblastic
lymphoma - T-cell |
High |
|
|
|
|
Mature B-cell NHL: Markers CD19, 20, 22, 23
|
Most Common
Grade
|
Incidence
per year
|
Mortality
per year
|
Percentage of NHL
|
| Burkitt's |
High |
|
|
2% |
Chronic
lymphocytic leukemia/
small lymphocytic lymphoma (CLL/SLL) |
Low |
|
|
6% |
| CNS
(Central Nervous System) * |
High |
|
|
|
| Diffuse
large B-cell lymphoma |
High |
|
|
|
| Follicular
(center cell) lymphomas: |
Low |
|
|
|
large
cell (Grade 3)
|
High |
|
|
|
mixed
large and small (Grade 2)
|
Low |
|
|
|
small
cleaved (Grade 1)
|
Low |
|
|
|
| Hairy
cell leukemia |
Low |
|
|
|
| Large
Cell immunoblastic |
|
|
|
|
| Large
B-cell lymphomas: |
High |
|
|
|
Follicular
|
High |
|
|
|
Mediastinal
(thymic)
|
High |
|
|
|
| Mantle
cell lymphoma |
High |
|
|
6% |
| Marginal
zone lymphomas |
|
|
|
|
MALT
- mucosa associated:
|
Low |
|
|
5% |
gastric,
eye, skin, lung, salivary, orbit,
|
|
|
|
|
nasopharynx,
larynx, breast
|
|
|
|
|
Nodal
+/- Moncytotal b-cells
|
Low |
|
|
|
Splenic
with Villous Lymphocytes
|
Low |
|
|
|
| Plasma
cell myeloma / plasmacytomas |
|
|
|
|
| Primary
amyloidosis |
|
|
|
|
| Primary
effusion lymphoma |
|
|
|
|
| Solitary
plasmacytoma of bone |
|
|
|
|
| Waldenström’s
Macroglobulinemia (Lymphoplasmacytic) |
|
|
|
1% |
T-cell and NK-cell NHL
(Mature cell stage unless "precursor
cell" is indicated)
Markers CD2, 3, 4, 5, NK: CD16, 56
|
Most Common
Grade
|
Incidence
per year
|
Mortality
per year
|
Percentage of NHL
|
| Adult
T-cell |
High |
|
|
|
| Aggressive
NK cell leukemia |
High |
|
|
|
| Anaplastic
large cell lymphoma - CD30 positive
Subtype: Ki-l-positive |
|
|
|
|
| Angioimmunoblastic
T-cell lymphoma (13%) |
|
|
|
|
| Blastic
NK cell lymphoma (precursor cell) |
|
|
|
|
| Enteropathy
type T-cell lymphoma |
|
|
|
|
| Extranodal
NK/T cell lymphoma, nasal type (Angiocentric) |
High |
|
|
|
| Gamma-delta
T-cell phenotype 1 - provisional
subtype |
|
|
|
|
| Hepatosplenic
T-cell lymphoma |
|
|
|
|
| Lymphomatoid
papulosis (uncertain malignant status) |
|
|
|
|
| Mycosis
fungoides - cutaneous (skin) t-cell lymphoma (CTCL) Subtype:
Angiocentric |
Low |
|
|
|
| Peripheral
T-cell lymphomas, unspecified |
|
|
|
15
-20% |
| Precursor
T-cell lymphoma (precursor cell) |
|
|
|
|
Primary
cutaneous anaplastic large cell lymphoma
(favorable prognosis) |
|
|
|
|
| Sezary
syndrome - leukemic form of Mycosis fungoides |
|
|
|
|
| Subcutaneous
panniculitis-like T-cell lymphoma |
|
|
|
|
| T-cell
Large granular lymphocytic leukemia |
|
|
|
|
| T-cell
proliferation of uncertain malignant potential |
|
|
|
|
| T-cell
prolymphocytic leukemia - T-cell CLL (1% of CLL) |
|
|
|
|
"About 85% of non- Hodgkin's lymphomas arise in B-cells; the rest
occur in T-cells. Activation of a gene called BCL-2 is believed to be
partly responsible for many B-cell lymphomas. This defect prevents
apoptosis in the lymphoma cells (a natural process whereby cells self-
destruct)."
"Lymphomas
are also grouped by certain properties:
Size (large versus small).
Shape (round versus irregular).
Whether they are or resemble blood plasma cells.
Whether they are follicular (organized in round clusters)
or diffuse
(spread evenly throughout the lymph node)."
- ucdavis.edu
Systems for classifying non-Hodgkin's Lymphoma
 |
Rappaport:
Based on morphology (how the cells look in the microscope)
alone; used until the 1970s.
|
 |
Kiel:
Based on morphologic and
immunologic (what types of proteins are produced by the cell)
characteristics; updated in 1992; used mainly in Europe
|
 |
National Cancer Institute's Working Formulation
(IWF): Divided lymphomas into low-grade, intermediate-grade and high-grade, with ten sub-groups labeled A to J.
|
 |
Revised European-American Classification of Lymphoid Neoplasms
(REAL): Describes the different types of lymphomas as entities, with each type classified according to
cell origin, based on morphologic,
immunologic and genetic
characteristics; introduced in 1994.
|
 |
World Health Organization
(WHO): Uses the latest information on the appearance and
growth pattern of the cancerous cells and genetic
features. It also offers a more accurate description of the different types of tumors and identifies several new categories of non-Hodgkin's lymphatic
cancer; updated version of REAL. Introduced in 2001 as an international standard. |
Resources
 |
Background
information on NHL - FDA
|
 | Table of contents-Lymphomas and Plasma cell
neoplasms - pathologyoutlines
|
 |
WHO
Classification of Tumors of Hematopoietic and Lymphoid Tissues - Cancer.gov
|
 |
The Revised European-American
Classification of Lymphoid Neoplasms (REAL classification) - umich.edu
Pathology of Lymphomas - ncl.ac.uk
|
|